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Summary 
The emergency management of ST-elevation myocardial infarction (STEMI) involves 
treatment with dual antiplatelet therapy (DAPT) and primary percutaneous coronary 
intervention (PPCI). Pain is generally treated with opiates, which may delay gastric transit, 
and reduce DAPT absorption. We sought to assess the effect of morphine on reperfusion, 
infarct size and thrombotic status in 300 patients presenting for PPCI. Morphine was given in 
a non-randomized fashion as required by emergency teams en route to the heart attack centre. 
All patients received DAPT and PPCI according to standard care, with optional glycoprotein 
IIb/IIIa inhibitor (GPI) use. Patients were assessed for ST-segment resolution, coronary flow, 
thrombotic status and peak troponin. Patients receiving morphine (n=218; 72.7%) 
experienced less spontaneous ST-segment resolution pre-PPCI, lower rate of TIMI 2/3 flow 
in the infarct-related artery pre-PPCI, and higher peak troponin level post-PPCI 
(median[IQR]; 1906[1002-4398] vs. 1268[249-2920] ng/L; p=0.016) than those who did not. 
Patients receiving morphine exhibited significantly enhanced platelet reactivity and impaired 
endogenous fibrinolysis on arrival, compared to no-morphine patients. Morphine 
administration was an independent predictor of failure of spontaneous ST-segment resolution 
after adjustment for other variables (OR 0.26; CI:0.08-0.84; p=0.025). Among patients 
receiving GPI, there was no difference in pre-PPCI flow or peak troponin according to 
morphine use, suggesting that the adverse effects of morphine relate to delayed DAPT 
absorption, that may be overcome by GPI. Our hypothesis-generating data suggest that 
morphine use in STEMI is associated with enhanced platelet reactivity, reduced spontaneous 
myocardial reperfusion (pre-PPCI) and larger infarct size, and these adverse effects may be 
influenced by GPI use. 
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Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: 
NCT02562690 
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What is known about this topic? 
• Opiate analgesia with morphine is frequently used to treat the symptoms of chest pain and 
related sympathetic activation in patients with ST-elevation myocardial infarction.  
• The early administration of oral antiplatelet agents upstream of angiographic assessment 
and PPCI, is recommended by guidelines to improve clinical outcomes. 
• Morphine administration reduces the onset and the antiplatelet effect of orally-administered 
P2Y12 inhibitors, but whether this affects clinical outcomes is not clear. 
What does this paper add? 
• In the largest study to-date examining the effects of morphine in patients with STEMI 
undergoing PPCI, morphine use was associated with both enhanced platelet reactivity and 
with impaired endogenous fibrinolysis. 
• Morphine use was associated with reduced occurrence of spontaneous coronary reperfusion 
pre-PPCI and non-independently associated with larger infarct size.  
• The adverse effects of morphine in patients with STEMI may be favourably influenced by 
upfront GPI administration. 
 
 
 
 
 
Abbreviations 
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ACS = acute coronary syndrome 
HAC = heart attack centre 
DAPT = dual antiplatelet medication  
GPI = glycoprotein IIb/IIIa inhibitor 
GTT = global thrombosis test 
LT = lysis time 
OT = occlusion time 
PPCI = primary percutaneous coronary intervention 
STEMI = ST-elevation myocardial infarction 
TIMI = Thrombolysis in Myocardial Infarction 
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Introduction 
The emergency management of ST-elevation myocardial infarction (STEMI) involves the 
administration of dual antiplatelet medication (DAPT) and revascularization with primary 
percutaneous coronary intervention (PPCI). Guidelines recommend analgesia for the relief of 
pain and to reduce associated sympathetic activation (1). Conventionally, morphine or 
diamorphine is used, which may delay gastric transit, and reduce absorption of DAPT. 
Pharmacodynamic and pharmacokinetic studies have shown that morphine use decreases the 
concentration and effects of P2Y12 inhibitors (2), and is associated with reduced platelet 
inhibition (3-5). In a crossover study of 11 patients, coadministration of morphine delayed the 
onset of prasugrel’s antiplatelet effect (6). In a pre-specified substudy of the ATLANTIC trial 
in 37 patients undergoing PPCI, morphine delayed the onset of action of ticagrelor as 
measured by vasodilator-associated stimulated phosphoprotein (VASP) platelet reactivity 
index and VerifyNow (7). In 300 patients with STEMI receiving prasugrel or ticagrelor, 
morphine administration was an independent predictor of high residual platelet reactivity 2 
hours post-PPCI (8). 
The MOJITO study showed that administration of ticagrelor in crushed form in STEMI 
patients achieved earlier platelet inhibition than whole tablets, but even in this group, 
morphine use was associated with higher on-treatment platelet reactivity (9). In the 
IMPRESSION trial, 70 patients with acute coronary syndrome (ACS; namely STEMI or non 
STEMI) were randomised to receive intravenous morphine or placebo followed by 180mg 
ticagrelor. Platelet reactivity was assessed with VASP, multiple electrode aggregometry and 
VerifyNow. All 3 tests showed that morphine delayed and attenuated the effect of ticagrelor 
(4). In 182 patients undergoing PPCI, of whom 72 received morphine, morphine use was 
associated with higher residual platelet reactivity measured by VerifyNow and reduced 
myocardial reperfusion post-PPCI. However, independent predictors of impaired myocardial 
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reperfusion after PCI were high residual platelet reactivity and TIMI flow grade after PPCI 
but not morphine use, questioning the direct relationship between morphine and reduced 
myocardial reperfusion (3).  
Thus, the relationship between morphine use, myocardial reperfusion and infarct size remains 
contentious, at least in part due to the small size of prior studies. We sought to assess 
thrombotic status of STEMI patients undergoing PPCI, according to morphine use and relate 
this to coronary reperfusion, infarct size and clinical outcome. 
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Methods 
Study design and population 
We performed a prospective, single centre study, approved by the National Research Ethics 
Committee, enrolling patients presenting for emergency PPCI after obtaining informed 
consent. We included adults (≥18 years) with a presumed diagnosis of STEMI based on 
clinical presentation and ECG criteria (namely: new ST-elevation at the J-point in ≥2 
contiguous leads of ≥2mm [0.2mV] in men or ≥1.5mm [0.15mV] in women in leads V2–V3 
and/or of ≥1mm [0.1mV] in other contiguous chest leads or limb leads, or ST-depression in 
≥2 precordial leads [V1–V4], or new or presumably new left bundle branch block in patients 
with clinical suspicion of ongoing myocardial ischaemia) (10). All patients received aspirin 
300mg and either clopidogrel 600mg or ticagrelor 180mg in the ambulance or emergency 
department upon diagnosis, before arrival at the heart attack centre (HAC). Patients receiving 
clopidogrel (rather than ticagrelor) pre-arrival to the cardiac catheterisation laboratory were 
loaded with ticagrelor 180mg orally peri-PPCI (after the first blood sample was taken) and 
continued on this post-procedure. Chest pain described by the patient as severe was treated by 
the emergency team with intravenous morphine (5-10mg), together with ondansetron for the 
prevention of nausea and vomiting, en route to the HAC. Patients who were vomiting 
following DAPT loading pre-PPCI, those intubated and ventilated, unable to swallow, those 
receiving oral anticoagulation, those with known coagulation disorders or platelet count 
<100x109/L, haemoglobin <80g/L, known active malignancy, or inability to take DAPT, 
were excluded.  
 
Blood sampling for thrombotic status 
Blood was taken at 2 time points: 1) baseline upon arrival to the catheterisation laboratory 
(after DAPT loading, day 0), prior to heparin or glycoprotein IIb/IIIa inhibitor (GPI) 
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administration and before PPCI, and 2) on day 2 of admission (on DAPT), 2-4 hours after the 
morning dose of DAPT. Fasting was not required. 
The first blood samples were taken from a 6-F radial or femoral sheath using a 2-syringe 
technique. The second samples were taken from an antecubital vein using an 18-G butterfly 
cannula also using a 2-syringe technique, taking care to avoid prolonged tourniquet time. The 
2-syringe technique involved using the first 5ml blood for routine blood tests and the second 
5ml for thrombotic status assessment. Prior data had shown no difference in thrombotic status 
between simultaneously collected arterial and venous blood samples. 
 
Assessment of global thrombotic status  
The Global Thrombosis Test (GTT) (Thromboquest Ltd., London, UK), an automated point-
of-care test, was used to assess both platelet reactivity and endogenous fibrinolysis from a 
native, non-anticoagulated blood sample. Measurement of thrombotic status was performed 
blinded to opiate use. The instrument was positioned in the catheterisation laboratory, ready 
to use. After the blood sample was obtained, it was introduced into the GTT cartridge within 
15 seconds of withdrawal and the automated measurement begun. The instrument assesses 
the time taken to form an occlusive thrombus under high shear stress (occlusion time, OT), 
and the time required to restore flow through endogenous fibrinolysis (lysis time, LT). The 
principle of the GTT has previously been described in detail (11). In brief, blood flows under 
high shear through narrow gaps inside the conical tube where thrombus formation occurs and 
the instrument measures the time (d) between 2 consecutive blood drops downstream of this. 
This time interval increases gradually as flow slows and at an arbitrary point (d≥15s, before 
reaching complete occlusion), the end point of the measurement is displayed (occlusion time 
[OT], seconds). Restart of blood flow after occlusion is due to spontaneous fibrinolysis (lysis 
time [LT], seconds). If lysis does not occur until >6,000s (LT cut-off time), “no lysis” is 
 10 
recorded. The coefficient of variation (cv) was assessed by testing 10 stable patients on 2 
occasions, 48 hours apart.  
 
PPCI procedure 
The procedure was performed according to standard clinical care. Unfractionated heparin 
(UFH) was given at a dose of 70-100 U/kg immediately before PPCI, with additional boluses 
to maintain the activated clotting time >250 seconds. Use of GPI was at the operator’s 
discretion, in conjunction with UFH. Decisions regarding access site, thrombus aspiration, 
and stent type were left to the operator.  
 
ECG and Angiographic Analyses 
ECG and angiographic analyses were performed by an investigator blinded to morphine use, 
thrombotic status results and not involved in the PPCI procedure. Standard 12-lead ECGs 
were obtained on arrival in the HAC and compared to that at baseline (in ambulance or 
emergency department). ECGs were analyzed using a hand-held caliper. The ST-segment 
was measured 20ms after the J-point, and the sum of ST deviation was measured as 
previously described (12). The percent resolution of ST deviation from baseline to arrival was 
calculated, and categorized using Schröder’s 3-component definition: complete (≥70%), 
partial (30-70%) and no (≤30%) ST-segment resolution. Flow in the infarct-related artery was 
reported using the Thrombolysis in Myocardial Infarction (TIMI) flow grading system and 
patency defined as TIMI grade 2 or 3 flow. 
 
Data collection and follow-up 
Patient case-notes were checked throughout the course of the index admission, to allow 
contemporaneous data collection. Patients were followed up at 30 days in person for the 
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occurrence of death, new MI (based on the universal definition of myocardial infarction 
according to European Society of Cardiology [ESC] guidelines) (13) including acute stent 
thrombosis (defined according to the Academic Research Consortium criteria), or stroke, as 
well as for major and minor bleeding, classified according to the Bleeding Academic 
Research Consortium (BARC) definition (14). For all endpoints, source documents were 
obtained and diagnosis verified by 2 clinicians blinded to medication or GTT results.  
 
Statistical analysis 
Since there is no reference study examining the effect of morphine on troponin level in 
STEMI patients, we performed an internal pilot study of 51 patients to estimate final sample 
size. The troponin levels of patients who had (n=38) and had not received morphine (n=13) 
were 3922±1225 and 3472±987 ng/L, respectively. Based on this and assuming a two-sided 
alpha value of 0.05 and 3:1 ratio, we calculated using the t-test for independent variables, that 
enrolment of 284 patients would provide 80% power to demonstrate a significant difference 
in troponin values between patients who did and did not receive morphine. We recruited 300 
patients to achieve suitable numbers for analysis. 
Data are presented as mean and standard deviation (when normally distributed) or median 
and inter-quartile range (IQR, if non-normally distributed). Dichotomous variables were 
compared using chi-square test or Fisher’s exact test, as appropriate. Correlations were 
analysed using Pearson's or Spearman's method, dependent on distribution. Patients were 
divided into two groups according to morphine use and subsequently also according to GPI 
use. Effects of clinical and angiographic variables, medications, and ECG parameters on 
thrombotic status were assessed.  
Univariate and multivariate linear regression models were used to identify the independent 
predictors of peak troponin and binary logistic regression for ST-segment resolution failure. 
All the study variables listed in Tables 1, 2 and 3, were first analysed with univariate analysis 
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and those that showed a significant interaction (p<0.05) were entered into the multivariate 
analysis. Significance was taken as <0.05. Analyses were performed with Stata V.11.2 
(StataCorp, College Station, Texas, USA).   
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Results  
Between April 2015 and June 2016, 337 patients presenting for emergency PPCI were 
eligible for recruitment. Four patients were already enrolled in the trial and 33 met ≥1 
exclusion criteria. All survivors were followed up at 30 days. Intravenous morphine was 
given pre-hospital in 218 (72.7%) patients with intravenous ondansetron 4mg, given 
simultaneously. Patient characteristics are shown in Tables 1-3. Patients in the morphine and 
no-morphine groups were well matched for baseline characteristics. 
Among patients who had received morphine, complete ST-segment resolution pre-PPCI was 
far less frequently observed (9.2 vs. 31.7%, p<0.001) and angiographic flow in the infarct-
related artery was significantly reduced prior to PCI (21.6 vs. 48.8%, p=0.001) compared to 
those who had not received morphine (Figure 1 and Table 3).  
Morphine-treated patients exhibited enhanced platelet reactivity on arrival, as evidenced by 
shorter OT, and impaired endogenous fibrinolysis (longer LT) compared to patients without 
morphine (Table 2). The difference in OT was no longer apparent by day 2, although LT 
remained slightly longer in the morphine-treated group (Table 2). 
Patients receiving morphine had significantly higher peak troponin than those not receiving 
morphine (1906[1002-4398] vs. 1268[249-2920]; p=0.016), with a positive correlation 
between morphine use and troponin level (r=0.2, p=0.012). 
Subgroup analysis showed that within the group of patients who received GPI (n=101), there 
was no difference in pre-PPCI coronary flow or peak troponin according to morphine use 
(Table 4).  
Of all variables in Tables 1-3, univariate analysis showed that only the following were related 
to peak troponin level and were subsequently entered into the multiple linear regression 
analysis: ST-segment resolution failure (p=0.001), TIMI 0/1 angiographic flow pre-PPCI 
(p<0.001), impaired left ventricular function (p<0.001), anterior STEMI (p=0.019), baseline 
neutrophil count (p=0.002), and prior calcium antagonist use (p=0.043). Morphine use did 
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not predict peak troponin. Using multivariate linear regression, only anterior STEMI 
(p=0.020) and high neutrophil count (p=0.001) were independent predictors of troponin 
levels after adjustment for the other variables. 
Of all variables in Tables 1-3, the following variables identified on univariate analysis were 
related to ST-segment resolution: morphine use (OR 0.21; CI:0.11-0.39; p<0.001), troponin T 
level (OR 0.95; CI:0.93-0.98; p<0.001), anterior STEMI (OR 0.53; CI:0.27-0.97; p=0.047), 
and pain to first device time (OR 0.34; CI:0.11-0.99; p=0.049). These variables were entered 
into the multivariate logistic regression analysis to identify independent predictors of ST-
segment resolution. Only peak troponin (OR 0.93; CI:0.91-0.95; p<0.001) and morphine use 
(OR 0.26; CI:0.08-0.84; p=0.025) remained independent predictors of ST-segment resolution 
after adjustment for other variables.  
There was no significant difference in the event rates between the groups (Tables 5 and 6). 
However, numerically more MACE events were observed in the morphine group. 
The cv was 8% for OT and 10% for LT. There was a negative correlation between baseline 
OT and neutrophil count (r= -0.2, p=0.004), platelet count (r= -0.2, p=0.016) and baseline LT 
(r= -0.3, p<0.001). There was a positive correlation between baseline OT and fibrinogen (r= 
0.2, p=0.007) and day 2 OT (r= 0.4, p<0.001). No other clinical, laboratory or angiographic 
parameters correlated with baseline OT or LT. There was no difference in the time of day at 
presentation between morphine and no-morphine groups (p=0.734), and no relationship 
between time of presentation and baseline OT (p=0.298) or LT (p=0.542). 
 
 
 
Discussion  
In the largest study to date assessing the effect of morphine in STEMI, our non-randomized 
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data show that morphine administration is associated with impaired thrombotic status at 
presentation (evidenced by enhanced platelet reactivity and impaired endogenous 
fibrinolysis), reduced rate of spontaneous ST-segment resolution, reduced epicardial coronary 
flow pre-PPCI and higher peak troponin. Additional treatment with GPI appears to 
favourably influence these effects of morphine. 
Spontaneous reperfusion, reported in 15% of patients with STEMI (15) is associated with a 
lower adverse event rate compared with persistent ST-segment elevation (16). Whilst a 
previous study showed no impact of morphine on reperfusion assessed 30 minutes following 
PPCI (3), we show that morphine use is associated with a significantly lower rate of 
spontaneous reperfusion (pre-PPCI) and is an independent predictor of failure of ST-segment 
resolution after adjusting for other variables. Furthermore, despite successful 
revascularization with similar post-PPCI coronary flow, peak troponin was significantly 
higher in the morphine group. Peak troponin levels following STEMI correlate closely with 
infarct size on cardiac MRI (17) and SPECT (18). The higher troponin level seen here in 
morphine-treated patients do not prove a causative association, but are supported by the 
larger infarct and lower myocardial salvage index on cardiac MRI following PPCI in 
morphine-treated patients (19). However, the larger infarct size did not translate into an 
increase in short-term adverse events, perhaps due to small sample size, coupled with 
relatively high use of GPI in our study, that may overcome the adverse effects of morphine.  
The association of morphine with reduced flow, impaired thrombotic status and greater 
troponin rise may simply reflect the fact that patients with more extensive infarcts have more 
pain and analgesia requirement. Conversely, patients with efficient endogenous fibrinolysis 
may more frequently exhibit spontaneous reperfusion, thus have lower analgesia 
requirements and less troponin rise. However, in clinical practice, the extent of infarction is 
not always mirrored by the level of morphine requirement or administration. Variation in pain 
threshold between individuals, as well as degree of supporting collaterals, may affect the 
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intensity of pain experienced; furthermore, medical staff including paramedics have varying 
thresholds for administering analgesia. A randomized trial could address this confounder, but 
might face ethical challenges. 
The apparent adverse effect of morphine is likely to be attributable, at least in part, to reduced 
gastric motility and delayed absorption of antiplatelet medication, and not a simple 
association of need for morphine with extensive infarction. This is supported by data from the 
IMPRESSION trial, which demonstrated reduction in the pharmacokinetic, 
pharmacodynamic and anti-platelet effects of ticagrelor when combined with morphine, 
compared to placebo (4).  
Our study confirms and significantly enhances the findings of two earlier, small studies, of 70 
(35 morphine-treated) (4) and 182 (74 morphine-treated) patients (3) showing that morphine 
attenuated P2Y12 inhibitor effect in PPCI patients. Our trial is not only significantly larger, 
with 218 morphine-treated patients, but we show both an impact on platelet reactivity and an 
adverse relationship between morphine administration and spontaneous reperfusion pre-PPCI 
and infarct size post-PPCI. 
High platelet reactivity is a marker of adverse outcome in the settings of ACS and PCI (20). 
The association of morphine use with enhanced platelet reactivity upon arrival, is likely 
attributable to delayed DAPT absorption. The mechanism linking P2Y12 inhibition with 
enhanced reperfusion pre-PPCI is not clear. Data suggest that P2Y12 inhibitors and GPI not 
only prevent formation of a stable arterial thrombus, but also loosen the formed thrombus, 
causing it to disperse. Platelet thrombi formed by perfusing blood over collagen were 
completely dispersed by the P2Y12 inhibitor cangrelor or a GPI (21), and P2Y12 inhibitors 
including clopidogrel, have been shown to destabilize platelet-platelet contacts, leading to 
thrombus disaggregation (22, 23). We postulate that morphine, by delaying DAPT 
absorption, attenuated P2Y12 inhibitor effect, leading to delay in destabilizing platelet-platelet 
contacts, resulting in prolonged endogenous fibrinolysis. Although tirofiban was given only 
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in the catheterisation laboratory, the rapid onset of action may explain the improved flow pre-
PPCI and reduced peak troponin. This is conjecture only and future prospective, randomised 
trials would be required to confirm this. 
Endogenous fibrinolysis is a natural protective mechanism against lasting infarction (24), and 
impaired fibrinolysis is a marker of adverse prognosis in ACS (11) and STEMI (25). We 
observed a significant association between morphine administration and impaired 
endogenous fibrinolysis on arrival. The lower fibrinogen levels in patients receiving 
morphine, coupled with impaired endogenous fibrinolysis, may indicate systemic activation 
of the clotting system with consumption of clotting factors exceeding synthesis.   
There is mounting evidence that opiate-use in the setting of STEMI may be harmful (3, 4, 
26). Although in healthy volunteers, morphine significantly decreased the plasma 
concentrations of prasugrel (27) and ticagrelor (28) and their active metabolites, interestingly, 
morphine did not diminish the pharmacodynamic effects of these P2Y12 inhibitors on platelet 
aggregation. However, this is a very different scenario to patients with coronary disease and 
those with acute coronary disease. Kubica and co-workers elegantly reviewed the possible 
mechanisms of the drug-drug interaction between morphine and P2Y12 inhibitors, showing 
delay in pharmacokinetics, mirrored by delay in pharmacodynamic effects on platelet 
reactivity (29). This appears to be a class effect, with fentanyl administration also recently 
shown to also lower plasma concentrations of ticagrelor and delay its antiplatelet effects in 
the PACIFY trial (30). Options to overcome this include the use of non-opiate analgesia pre-
hospital (such as intravenous paracetamol), or parenteral administration of P2Y12 inhibitor, 
such as cangrelor, although cost is likely to be a deterrent for routine use (26, 29). Crushed 
ticagrelor is absorbed more quickly than oral tablets (9) and faster via a crushed oral 
compared to crushed sublingual route (31). Upfront GPI use may alleviate the adverse effect 
of morphine, since amongst patients receiving GPI, there was no difference in epicardial 
coronary flow pre-PPCI, nor in peak troponin, according to morphine use. Our data are 
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supported by an earlier small study in STEMI patients, showing that the delayed onset of 
platelet inhibition by prasugrel due to co-administration of morphine was overcome by 
intravenous abciximab (32) and in clopidogrel nonresponders, GPI  use lowered the rate of 
cardiovascular events after elective PCI (33). Tirofiban is a small, nonpeptide molecule, with 
a short half-life and marked specificity for the GPIIb/IIIa receptor. Abciximab, a large 
monoclonal antibody directed against β3 integrin, has a prolonged half-life, and also binds to 
αvβ3 integrin and to white-cell αMβ2 integrin receptors. Both agents are highly effective at 
blocking platelet-platelet interactions, but since abciximab can also inhibit platelet adhesion 
to endothelial cells and to white cells, there has been debate whether it may be superior to 
tirofiban (34, 35). Although tirofiban offered less protection from ischaemic events than 
abciximab in the TARGET trial (36), STEMI patients were excluded. A subsequent meta-
analysis concluded that in PPCI patients, GPI provided a “class effect” benefit that extended 
also to small molecules such as tirofiban (34).  But perhaps it is not the agent, but the timing 
of administration that matters most. Very early abciximab use pre-PPCI achieved an 89% 
reduction in the six-month end-point and enhanced TIMI 3 flow pre-PPCI >3-fold (35). 
Tirofiban administration ~33 minutes pre-PPCI significantly improved initial epicardial flow 
and myocardial perfusion compared to administration in the catheterisation laboratory (37). 
Whilst our current use of GPI is predominantly for high thrombus burden or bail-out during 
PPCI, consistent with the class IIa recommendation from guidelines (1, 38), in the present 
study tirofiban was administered at the operator’s discretion at a variable timepoint, from 
presentation to just before PCI. Although it is not possible to derive the exact time between 
GPI administration and first culprit vessel image (due to documentation), we speculate that 
this would average 5-10 minutes. This is a shorter timeframe than that previously evaluated 
but benefits are consistent with the known rapid onset of effect. Whilst the observed 
relationship between GPI use and pre-PPCI coronary flow may be due to chance, the 
relationship with reduced troponin post-PPCI is consistent with earlier studies. Whilst routine 
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use in the PPCI setting remains contentious, there may be a selective role for GPI in patients 
who receive opiate analgesia, where DAPT absorption may be delayed.  
Anti-emetics are frequently co-administered with opiates. Metoclopramide stimulates upper 
gastrointestinal tract motility, which may antagonise the adverse effects of opioid analgesia 
on the gut (29). Ondansetron, unlike metoclopramide, is not a pro-kinetic agent but whether it 
adversely impacts on upper gastrointestinal motility is contentious. It may slow whole gut 
transit, cause constipation, and reduce fasting antroduodenal motility (39). Whether 
metoclopramide may offer an advantage over ondansetron with regard to DAPT absorption, 
requires investigation.  
 
Study limitations 
The main limitation of our study is that this was not a randomized controlled trial. A potential 
confounder resulting from the observational nature of this study, is that patients without 
spontaneous reperfusion may have more pain and greater analgesia requirement. Enhanced 
sympathetic activation in those with more pain might also influence thrombotic status 
through direct and indirect cholinergic effects on platelet aggregation. It would be unethical 
to withhold potent analgesia from STEMI patients and currently there are no suitable 
alternatives in the pre-hospital setting for routine use. However, the groups were well 
matched for baseline clinical, angiographic and haematological/biochemical profiles. 
Secondly, the majority of patients received clopidogrel pre-PPCI, whilst the ESC 
recommends prasugrel or ticagrelor in this setting, because of their faster onset of action, 
greater potency and superiority over clopidogrel in large outcome trials (1). However, in most 
of the United Kingdom, clopidogrel remains the standard P2Y12 inhibitor administered in the 
ambulance, due to cost and complex funding arrangements, and this is also the case in many 
other European countries. Whilst the use of clopidogrel clearly impacts on the translatability 
of our results to a population receiving these more potent agents, the applicability of our data 
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is supported by similar adverse effects seen with morphine when patients received ticagrelor 
or prasugrel for PPCI (3). Furthermore, although most patients received clopidogrel, they 
were loaded with ticagrelor peri-PPCI and earlier data from the ATLANTIC (Administration 
of Ticagrelor in the Cath Lab or in the Ambulance for New ST Elevation Myocardial 
Infarction to Open the Coronary Artery) study has shown that pre-PPCI coronary reperfusion 
was similar whether ticagrelor loading was given pre-hospital or in the catheterisation 
laboratory (31). There were statistically more stents per patient implanted in the morphine 
than in the no-morphine group, although this difference was small, and stent diameter was 
similar between groups. We think this is unlikely to have impacted on 30 day outcomes, 
particularly as stent length, if anything, would more likely predispose to stent thrombosis, but 
this was not observed at follow up. 
Conclusions 
In the largest study to-date examining the effects of morphine in STEMI, our non-randomized 
data show that morphine use is associated with enhanced platelet reactivity and impaired 
endogenous fibrinolysis, reduced occurrence of spontaneous reperfusion pre-PPCI and non-
independently associated with larger infarct size, and that these adverse effects of morphine 
may be influenced by GPI administration. 
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Figure 1  
Spontaneous reperfusion pre-PPCI, peak troponin and in-hospital adverse events in 300 
patients with STEMI, according morphine use. 
TIMI=Thrombolysis in Myocardial Infarction, MACE=major adverse cardiovascular events 
(see text). *=P<0.02  
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Table 1: Baseline Patient Characteristics 
 
Whole Group  
(n=300)  
Morphine  
(n=218)  
No Morphine  
(n=82)  
P Value  
Age, yrs  64±13 64±13 63±12 0.457 
Male  236(78.7) 170(78.0) 66(80.5) 0.923 
Cardiogenic shock 18(6.0) 15(6.9) 3(3.7) 0.418 
Diabetes mellitus  52(17.3) 34(15.6) 18(22.0) 0.318 
Active smoker  99(33.0) 75(34.4) 24(29.3) 0.601 
Hypertension  151(50.3) 107(49.1) 44(53.7) 0.739 
Prior CAD 43(14.3) 31(14.2) 12(14.6) 1.000 
Prior MI 34(11.3) 24(11.0) 10(12.2) 0.840 
Prior PCI 33(11.0) 25(11.5) 8(9.8) 0.837 
Prior CABG 4(1.3) 3(1.4) 1(1.2) 1.000 
Renal insufficiency 12(4.0) 6(2.8) 6(7.3) 0.104 
PVD 13(4.3) 8(3.7) 5(6.1) 0.527 
Prior CVA 11(3.7) 9(4.1) 2(2.4) 0.733 
Prior aspirin use  50(16.7) 36(16.5) 14(17.1) 1.000 
Prior P2Y12 inhibitor use 11(3.7) 9(4.1) 3(3.7) 1.000 
P2Y12 inhibitor loading agent  
    
          Clopidogrel 259(86.3) 189(86.7) 70(85.4) 1.000 
          Ticagrelor 41(13.7) 29(13.3) 12(14.6) 0.853 
Time from P2Y12 inhibitor loading to first 
blood sample (min) * 
46[38-59] 47[36-60] 46[39-58] 0.740 
Medications on Day 2  
    
Aspirin  291(97.0) 212(97.2) 79(96.3) 1.000 
Ticagrelor  237(79.0) 174(79.8) 63(76.8) 0.922 
Clopidogrel 52(17.3) 38(17.4) 14(17.1) 1.000 
Prasugrel 2(0.7) 1(0.5) 1(1.2) 0.475 
Beta-blocker  266(88.7) 194(89.0) 72(87.8) 1.000 
ACE inhibitor  
Calcium antagonist 
269(89.7) 
23(7.8) 
198(90.8) 
13(6.0) 
71(86.6) 
10(12.2) 
0.850 
0.147 
Statin 
Nitrate  
Insulin 
283(94.3) 
14(4.7) 
15(5.0) 
206(94.5) 
10(4.6) 
9(4.1) 
77(93.9) 
4(4.9) 
6(7.3) 
1.000 
1.000  
0.375 
 
Values are mean±SD or n(%), except * where values median[IQR]. Renal insufficiency was defined as 
creatinine levels >177 μmol/L. Prior aspirin or P2Y12 inhibitor use defined as regular P2Y12 inhibitor use before 
hospitalisation.  
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ACE: angiotensin-converting enzyme, CABG: coronary artery bypass grafting, CAD: coronary artery disease, 
CVA: cerebrovascular accident, MI: myocardial infarction, PCI: percutaneous coronary intervention, PVD: 
peripheral vascular disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Haematological and biochemical profiles 
 Whole Group  
(n=300)  
Morphine  
(n=218)  
No Morphine  
(n=82)  
P Value  
 30 
Haemoglobin (g/L) * 139±16 139±16 138±17 0.899 
Haematocrit (%) * 42±5 42±5 42±5 0.897 
Neutrophil count (x109/L) 7.3[5.7-9.4] 7.4[5.8-9.6] 7.0[5.5-8.6] 0.264 
Platelet count (x109/L) 238[197-277] 242[199-285] 229[196-268] 0.209 
Creatinine (µmol/L)   81[70-95] 81[70-95]  86[71-99] 0.178 
Peak troponin T (ng/L) 1798[736-3961] 1906[1002-4398] 1268[249-2920] 0.016 
Fibrinogen (g/L) 4.4[3.8-5.0] 4.3[3.8-4.9] 4.6[4.1-5.4] 0.021 
Total cholesterol (mmol/L) 5.2[4.2-5.9] 5.2[4.2-5.9] 5.2[4.5-5.9] 0.521 
Baseline OT (sec) * 400±179 347±150 547±182 <0.001 
Day 2 OT (sec) * 477±132 469±128 488±143 0.339 
Baseline LT (sec) 1358[1107-1684] 1402[1159-1809]  1185[1029-1541] 0.001 
Day 2 LT (sec) 1321[1165-1582] 1332[1184-1584] 1220[1131-1478] 0.034 
 
Values are median[IQR], except * where values are mean±SD. LT: lysis time; OT: occlusion time. All values 
measured at presentation, except peak troponin and day 2 OT and LT. 
Normal values: haemoglobin 130-180g/L (males) and 115-165g/L (females); haematocrit 40-52% (males) and 
36-47% (females); neutrophil count 2-7.5x109/L; platelet count 150-400x109/L; creatinine 60-110μmol/L 
(males) and 45-90μmol/L (females); troponin T<14 ng/L (Elecsys high-sensitivity assay, Roche Diagnostics); 
fibrinogen 2–4 g/L; total cholesterol ≤4.0 mmol/L. 
 
 
 
 
 
 
 
 
Table 3: Angiographic, Interventional and Echocardiographic Patient Characteristics 
 
Whole Group  
(n=300)  
Morphine  
(n=218)  
No Morphine  
(n=82)  
P Value  
 31 
ST-segment resolution on ECG pre-PPCI 49(16.3) 21(9.6) 28(34.1) <0.001 
          Complete (≥70%) 46(15.3) 20(9.2) 26(31.7) <0.001 
          Partial (30% to 70%) 3(1.0) 1(0.4) 2(2.4) 0.187 
TIMI 2/3 angiographic flow pre-PPCI 87(29.0) 47(21.6) 40(48.8) 0.001 
TIMI 2/3 angiographic flow post-PPCI 292(97.3) 213(97.7) 79(96.3) 1.000 
Myocardial blush grade 2/3 post-PPCI * 281(93.7) 203(93.1) 78(95.1) 0.926 
Systolic blood pressure (mmHg) on arrival 136[119-158] 135[117-154] 140[120-168] 0.052 
Diastolic blood pressure (mmHg) on 
arrival 
80[68-90] 80[68-90] 82[69-99] 0.249 
Heart rate (bpm) on arrival 77[66-90] 75[65-90] 80[70-89] 0.188 
Killip classification 
    
          Score≤2 275(91.7) 200(91.7) 75(91.5) 1.000 
          Score>2 25(8.3) 18(8.3) 7(8.5) 1.000 
Arterial access 
    
          Radial 258(86.0) 185(84.9) 73(89.0) 0.850 
          Femoral 42(14.0) 33(15.1) 9(11.0) 0.462 
1-vessel disease 124(41.3) 94(43.1) 30(36.6) 0.546 
2-vessel disease 94(31.3) 64(29.4) 30(36.6) 0.432 
3-vessel disease 80(26.7) 59(27.1) 21(25.6) 0.888 
Culprit vessel  
    
          LMS 6(2.0) 5(2.3) 1(1.2) 0.686 
          LAD 107(35.7) 86(39.4) 21(25.6) 0.122 
          LCA 52(17.3) 32(14.7) 20(24.4) 0.135 
          RCA 116(38.7) 89(40.8) 27(32.9) 0.456 
          Bypass graft 1(0.3) 1(0.5) 0 1.000 
Thrombus aspiration 58(19.3) 45(20.6) 13(15.9) 0.517 
Balloon predilatation 243(81.0) 181(83.0) 62(75.6) 0.696 
GPI (Tirofiban) use 101(33.7) 79(36.2) 22(26.8) 0.296 
Bivalirudin use 6(2.0) 5(2.3) 1(1.2) 0.686 
Balloon angioplasty only 16(5.3) 11(5.0) 5(6.1) 0.776 
Stent implantation  
    
           DES  250(83.3) 190(87.2) 60(73.2) 0.381 
           BMS  8(2.7) 8(3.7) 0 0.115 
Number of stents ** 1.25±0.87 1.33±0.87 1.04±0.85 0.009 
Stent diameter <3 mm  87(29) 66(30.3) 21(25.6) 0.477 
Door to first device time, min  29[22-35] 29[22-35] 30[21-36]  0.918 
Call to first device time, min 99[81-121] 97[79-121] 103[82-121] 0.420 
Pain to first device time, min 162[112-235] 160[112-236] 185[118-225] 0.755 
Left ventricular function  
    
 32 
             Normal (EF ≥55%) 117(39.0) 77(35.3) 40(48.8) 0.188 
             Mildly impaired (EF 45–54%) 72(24.0) 55(25.2) 17(20.7) 0.556 
             Moderately impaired (EF 36–44%) 73(24.3) 56(25.7) 17(20.7) 0.556 
             Severely impaired (EF ≤35%) 38(12.7) 27(12.4) 11(13.4) 0.848 
  
Values are median[IQR] or n(%), except ** where values are mean±SD. Left ventricular function was assessed 
by echocardiography prior to hospital discharge. 
BMS: bare metal stent, DES: drug eluting stent, EF: ejection fraction, GPI: glycoprotein IIb/IIIa inhibitor, LAD: 
left anterior descending coronary artery, LCA: left circumflex coronary artery, OM: obtuse marginal coronary 
artery, PPCI: primary percutaneous coronary intervention, RCA: right coronary artery, TIMI: Thrombolysis in 
Myocardial Infarction. 
Door to first device time was the delay between the arrival of a patient at the hospital and the time of first 
intracoronary device use (defined as time of first balloon or stent inflation; or use of thrombectomy or 
angioplasty wire if these re-established flow). Call to device time was the delay between a patient’s call for help 
and first device time. Pain to device time was the delay between the onset of symptoms and first device time.   
* All 19 patients (6.3%) who had final myocardial blush grade 0/1 showed ST-segment resolution failure and 
TIMI 0/1 angiographic flow pre-PPCI, and 5 out of 19 had TIMI 0/1 angiographic flow post-PPCI. 
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Table 4: Spontaneous reperfusion, thrombotic status and peak troponin, according to 
morphine and GPI use 
 
 
Values are median[IQR] or n(%), except * where values are mean±SD. GPI: glycoprotein IIb/IIIa inhibitor, 
PPCI: primary percutaneous coronary intervention, TIMI: Thrombolysis in Myocardial Infarction, LT: lysis 
time; OT: occlusion time. Troponin T<14 ng/L (Elecsys high-sensitivity assay, Roche Diagnostics).  
 
 
  
 
 
Whole 
Group 
(n=300) 
GPI 
(n=101) 
No GPI 
(n=199) 
 
P Value 
GPI vs 
No GPI 
 
Whole GPI 
group 
Morphine 
(n=79) 
(Group 1) 
No 
Morphine 
(n=22) 
(Group 2) 
P Value 
Group 1  
vs Group 2 
Whole No 
GPI group 
Morphine 
(n=139) 
(Group 3) 
No morphine 
(n=60) 
(Group 4) 
P Value 
Group 3 vs 
Group 4 
 
ST-segment resolution on 
ECG pre-PPCI 
 
 
49(16.3) 
 
6(5.9) 
 
2(2.5) 
 
4(18.2) 
 
0.029 
 
43(21.6) 
 
19(13.7) 
 
24(40.0) 
 
0.002 
 
0.002 
TIMI 2/3 angiographic 
flow pre-PPCI 
 
87(29.0) 9(8.9) 5(6.3) 4(18.2) 0.211 78(39.2) 42(30.2) 36(60.0) 0.017 <0.001 
TIMI 2/3 angiographic 
flow post-PPCI 
 
292(97.3) 98(97.0) 77(97.5) 21(95.5) 1.000 194(97.5) 136(97.8) 58(96.7) 1.000  1.000 
Peak troponin T (ng/L) 
 
 
 
1798[736-
3961] 
2646[1242-
4694] 
2508[1248-
5417] 
2879[1235-
3691] 
0.636 1448[548-
3030] 
1732[798-3796] 1030[151-
2313] 
0.018 0.007 
Baseline OT (sec) * 
 
 
400±179 373±202 321±154 559±242 <0.001 414±164 364±146 531±147 <0.001 0.066 
Day 2 OT (sec) * 
 
 
477±132 464±135 455±131 492±148 0.286 483±131 477±123 498±148 0.327 0.254 
Baseline LT (sec) 
 
 
 
1358[1107-
1684] 
1405[1107-
1673] 
1434[1140-
1697] 
1192[1025-
1555] 
0.061 1330[1105-
1711] 
1390[1169-
1850] 
1205[1042-
1537] 
0.003 0.919 
Day 2 LT (sec) 1321[1165-
1582] 
1314[1166-
1540] 
1326[1192-
1531] 
1268[1154-
1607] 
0.665 1321[1158-
1585] 
1354[1185-
1600] 
1218[1136-
1431] 
0.026 0.904 
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Table 5: In-Hospital Outcome 
Outcome Whole group 
(n=300) 
Morphine   
(n=218)  
No Morphine 
(n=82)  
P Value  
MACE (death, re-infarction, CVA) 12 10 2 0.525 
Death 6 4 2  1.000 
New myocardial infarction or re-infarction 3 3  0  0.566 
          Stent thrombosis 2 2 0 1.000 
Cerebrovascular accident 3 3 0  0.566 
Major bleeding (BARC type 3-5)  0 0  0  1.000 
Minor bleeding (BARC type ≤2)  2 0  2  0.077 
Pulmonary oedema  6 4  2  1.000  
Length of hospitalisation (days)  3[2-4]  3[2-4] 2.5[2-4] 0.515 
 
Values are n except length of hospitalisation (median[IQR]). MACE: major adverse cardiovascular events 
(cumulative of death, myocardial infarction and CVA), CVA: cerebrovascular accident, BARC: Bleeding 
Academic Research Consortium. 
 
All deaths were cardiovascular, defined as death in the presence of ACS, significant cardiac arrhythmia, or 
refractory congestive heart failure, or death attributed to cardiovascular cause at post-mortem. New MI or re-
infarction was defined according to the universal definition of myocardial infarction (13) as the detection of rise 
and/or fall of troponin T with at least one value >99th percentile of the upper reference limit and with at least 
one of the following: symptoms of ischaemia, new or presumably new significant ST-T changes or new LBBB, 
development of pathological Q waves in the ECG, imaging evidence of new loss of viable myocardium, or new 
regional wall motion abnormality, identification of an intracoronary thrombus by angiography, or stent 
thrombosis associated with myocardial ischaemia detected by coronary angiography. Stent thromboses were all 
acute, defined according to the Academic Research Consortium criteria. All CVA were ischaemic, defined as an 
acute focal infarction of the brain with one of the following: sudden onset of a new focal neurologic deficit, with 
clinical or imaging evidence of infarction lasting 24 hours or more and not attributable to a non-ischaemic 
cause, a new focal neurologic deficit lasting <24 hours and not attributable to a non-ischaemic cause but 
accompanied by neuroimaging evidence of new brain infarction.  
 
 
 
 
 
Table 6: 30-day Outcome 
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Outcome Whole group 
(n=300) 
Morphine   
(n=218)  
No Morphine 
(n=82)  
P Value  
MACE (death, re-infarction, CVA) 20 18 2 0.115 
Death  10 8 2  0.734 
New myocardial infarction or re-infarction 6 6 0 0.197 
          Stent thrombosis 3 3 0 0.566  
Cerebrovascular accident 4 4 0 0.344 
Major bleeding (BARC type 3-5)  2 1  1  0.999 
Minor bleeding (BARC type ≤2)  5 2  3 0.134 
Pulmonary oedema  12 9 3 1.000  
 
Values represent number of events. For abbreviations, see Table 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  
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